Literature DB >> 8819049

Fibrocartilaginous embolism of the spinal cord in dogs: review of 36 histologically confirmed cases and retrospective study of 26 suspected cases.

L Cauzinille1, J N Kornegay.   

Abstract

Clinical features of 36 dogs with histologically confirmed fibrocartilaginous embolism (FCE) were contrasted with those of 26 dogs in which FCE was suspected based on characteristic clinical findings and the absence of compressive spinal cord disease on myelography. Dogs with confirmed and suspected FCE were of similar signalment, and had acute, nonprogressive dysfunction, often associated with trauma or exercise. The "suspected" group included fewer giant breeds and more often had asymmetric lesions, intact nociception, and upper motor neuron involvement. Dog size and severity of clinical signs probably contributed to owners choosing euthanasia in dogs with confirmed lesions. Accordingly, data from such patients may be skewed relative to these clinical features.

Entities:  

Mesh:

Year:  1996        PMID: 8819049     DOI: 10.1111/j.1939-1676.1996.tb02056.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  14 in total

1.  Magnetic resonance imaging muscle lesions in presumptive canine fibrocartilaginous embolic myelopathy.

Authors:  Sabrina M Martens; Stephanie G Nykamp; Fiona M K James
Journal:  Can Vet J       Date:  2018-12       Impact factor: 1.008

2.  Fibrocartilaginous embolization to the spinal cord: serial MR imaging monitoring and pathologic study.

Authors:  Thierry P Duprez; Leslie Danvoye; Danielle Hernalsteen; Guy Cosnard; Christian J Sindic; Catherine Godfraind
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

3.  Fibrocartilaginous embolic myelopathy: demographics, clinical presentation, and functional outcomes.

Authors:  Brittany J Moore; Anna M Batterson; Marianne T Luetmer; Ronald K Reeves
Journal:  Spinal Cord       Date:  2018-05-25       Impact factor: 2.772

4.  Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.

Authors:  Wook-Hun Chung; Seon-Ah Park; Jae-Hoon Lee; Dai-Jung Chung; Wo-Jong Yang; Eun-Hee Kang; Chi-Bong Choi; Hwa-Seok Chang; Dae-Hyun Kim; Soo-Han Hwang; Hoon Han; Hwi-Yool Kim
Journal:  J Vet Sci       Date:  2013-06-28       Impact factor: 1.672

5.  Nucleus Polposus Embolism Causing Anterior Spinal Artery Occlusion: A Rare but Possible Cause of Fibrocartilaginous Embolic Myelopathy.

Authors:  Mayank Gupta; Harvinder Singh Chhabra
Journal:  Int J Spine Surg       Date:  2020-06-30

6.  Influence of Spinal Shock on the Neurorehabilitation of ANNPE Dogs.

Authors:  Débora Gouveia; Ana Cardoso; Carla Carvalho; Ana Rita Gonçalves; Óscar Gamboa; Rute Canejo-Teixeira; António Ferreira; Ângela Martins
Journal:  Animals (Basel)       Date:  2022-06-16       Impact factor: 3.231

7.  Usefulness of an early diagnosis for the favorable prognosis of fibrocartilaginous embolism diagnosed by magnetic resonance imaging in 10 small- to middle-sized dogs.

Authors:  Yuya Nakamoto; Tsuyoshi Ozawa; Kengo Katakabe; Koichi Nishiya; Tadahisa Mashita; Yutaka Morita; Nobuhiro Yasuda; Yuki Ishii; Munekazu Nakaichi; Kazuhito Itamoto
Journal:  Vet Res Commun       Date:  2008-05-20       Impact factor: 2.459

Review 8.  Challenges of stem cell therapies in companion animal practice.

Authors:  Min Hee Kang; Hee Myung Park
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

Review 9.  A Review of Fibrocartilaginous Embolic Myelopathy and Different Types of Peracute Non-Compressive Intervertebral Disk Extrusions in Dogs and Cats.

Authors:  Luisa De Risio
Journal:  Front Vet Sci       Date:  2015-08-18

10.  Prognostic Factors Associated with Recovery of Ambulation and Urinary Continence in Dogs with Acute Lumbosacral Spinal Cord Injury.

Authors:  T A Shaw; L De Risio; E J Laws; J H Rose; T R Harcourt-Brown; N Granger
Journal:  J Vet Intern Med       Date:  2017-04-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.